Levels of LL37 (the human derivation of cathelicidin) and β-defensin levels also showed greater variance in AD patients than healthy subjects (F = 8294 (p<0.0001), F = 3709 (p<0.0001), respectively) (Fig 1f and 1h). This evidence concerns the gene CAMP and Alzheimer disease.